Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Incepta Is Shaping Bangladesh's Vaccines Future

Executive Summary

Bangladesh's Incepta group has launched its vaccine bulk manufacturing facility – a move that could have a significant impact on cost dynamics in a country that imports over 90 million doses of vaccines each year under its infant immunization plan. Incepta's chair Abdul Muktadir tells Scrip why this facility can make a difference and also outlines plans on the firm's tetravalent HPV vaccine.

You may also be interested in...



Hilleman Eyes Bangladesh Approval Of Novel, Cheaper Cholera Vaccine This Year

Indian vaccine research organization Hilleman Laboratories says it is hoping to get its "new design", cheaper cholera vaccine licensed in Bangladesh this year and that the next step will be to seek to make it available to UN agencies amid remaining global inoculation need.

Incepta’s Vaccine Ambitions Bridled By Bangladesh Regulatory Gap

Bangladesh's Incepta Vaccine is gearing up for a larger play with vaccines for pneumonia and human papillomavirus in the pipeline, but a non-functional national regulatory authority in the country could stymie its ambitions in terms of large-scale supplies of other products to Unicef, at least in the short-term.

Divided House On Challenge Trials For COVID-19 Vaccines But Collaboration Goals Unite

High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel